ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0016525;negative regulation of angiogenesis;8.0;0.811012628672052;0.780506314336026;9.32314260294094;151.1079732353669;5.192106149009898;0.005057447875840929;0.6405245499179943;[FASLG, PRL, HHEX, EMILIN1, HOXA5, CCR2, DCN, HGS, CX3CR1, PLK2, TIE1, CXCL10, TEK, PF4]
GO:0014068;positive regulation of phosphatidylinositol 3-kinase signaling;8.0;1.0;0.875;9.628524252492122;238.41769229280743;5.602686357784832;0.007979625599047746;0.6615216408886768;[CCL5, PDGFD, PDGFC, FYN, PDGFRB, F2R, PTK2, DCN, FGR, GH1, KIT, CD28, PTPN6, TEK]
GO:0061333;renal tubule morphogenesis;6.0;0.7192862368539868;0.682763431017138;8.801845679307654;32.20947323359611;6.943860283624253;0.0010780220824845236;0.6782296504172152;[MEF2C, COL4A1, TACSTD2, LGR4]
GO:0008584;male gonad development;5.0;1.0;0.7902410118609202;9.628524252492122;50.96471695749156;5.2552850506314295;0.001705743211299806;0.5589965337459591;[HMGB2, LRP2, MEA1, HOXA11, HOXA10, PDGFRB, LHCGR, BIK, INHBA, EIF2S2, SFRP2, NASP, MSH2, KIT]
GO:0090179;planar cell polarity pathway involved in neural tube closure;10.0;1.0;0.9152410118609203;9.628524252492122;275.5135961891709;7.212124270218933;0.009221192118313007;0.7840693824379941;[SFRP2, CELSR1]
GO:0032330;regulation of chondrocyte differentiation;6.0;0.7671156992804218;0.7066781622303554;9.34084218004034;56.03372000150423;5.948432231191374;0.001875398181376348;0.6273234135236593;[ADAMTS12, RUNX2, CTGF, HOXA11, POR, EFEMP1]
GO:0043508;negative regulation of JUN kinase activity;13.0;1.0;0.9625549647676366;9.628524252492122;4937.625749520049;7.138016298065211;0.16525789026176277;0.8275934502023958;[DUSP10, SFRP2, PTPN22]
GO:0090177;establishment of planar polarity involved in neural tube closure;6.0;1.0;0.8231203125901445;9.628524252492122;28.093926463720614;9.083926447120524;9.40278435848416E-4;0.7876727335416686;[CTHRC1]
GO:0060401;cytosolic calcium ion transport;9.0;0.7248374789738407;0.7586593646672094;8.986670366319727;37.619827487335996;5.459585514144159;0.0012591017703544919;0.675444082270312;[FASLG, SLC8A1, CTGF, JPH2, CCR7, CCL19, CCR5, F2R, PTPRC, LCK, XCL1]
GO:0045766;positive regulation of angiogenesis;7.0;0.811012628672052;0.7564256795932265;9.303101852057495;134.49314513679974;4.7081694254602375;0.0045013645317563845;0.5916953686275062;[NRP1, CDH5, C3AR1, CTSH, GHSR, ANXA1, ANXA3, GAB1, SFRP2, IL1B, ADAM12, AGTR1, CHI3L1, ENG, CX3CR1, C5AR1, PTGS2, DLL1, CXCR2, PLCG1, JUP, PLK2, TNFSF12, LRG1, TEK]
GO:0001542;ovulation from ovarian follicle;4.0;1.0;0.75;9.628524252492122;27.16069640012757;7.697632086000634;9.090440654724862E-4;0.6436572628545723;[ADAMTS1]
GO:0071493;cellular response to UV-B;8.0;1.0;0.875;9.628524252492122;82.44278777713699;7.697632086000634;0.0027592859132088378;0.7686572628545723;[MFAP4, CDKN1A, MME]
GO:0030307;positive regulation of cell growth;6.0;0.6954798709641801;0.6708602480722345;8.712233520617966;80.64681300048527;4.733648510761223;0.0026991762537066665;0.5651993175676412;[CYFIP1, NRP1, CPNE5, CXCL16, RPS6KA1, AKT1, AVPR1A, SFRP2, S100A8, HBEGF, TAF9, PAK1, SFN, SYT2, CXCL12]
GO:0032967;positive regulation of collagen biosynthetic process;6.0;1.0;0.8231203125901445;9.628524252492122;105.22247330055487;6.558197802812269;0.003521701487291661;0.6585068532133508;[PDGFRB, TGFB1, MYB, F2R, ENG, CTGF]
GO:0045892;negative regulation of transcription, DNA-templated;10.0;0.556709148698489;0.6935955862101648;8.520155788878647;1581.2569993850602;2.683669001811703;0.05292324873051003;0.5524839694169422;[EHMT2, SLA2, PHB2, MYB, HOXA7, MEF2A, MEF2C, HOXB4, HOXB3, ATF3, PRDM16, ELANE, JUN, PKIG, EZH2, PAWR, PAX5, PAX2, AES, MMP12, BTAF1, FLNA, NR1H2, LGR4, GMNN, TNF, DACH1, MEN1, TLE4, FOXO1, NACC2, WFS1, NFKB1, BCL6, CIITA, FASLG, HHEX, EMILIN1, RFC1, XCL1, RBBP8, E2F7, KLF8, KLF5, DNAJA3, UXT, ZNF608, EDNRB, DPF3, RUNX2, SFRP2, PCBP3, EGR1, BCL11A, IFNA2, PTPRK, XPO1, CD36, IL1B, ARID4A, CHCHD3, BASP1, CCNE1, CALCA, TGFB1, CBX4, CAV1, HMGA1, NR4A2, MXD1, CREBZF, HMGB2, MYOCD, IFNG, ELF3, FBP1, PFDN5, MEIS2]
GO:0045893;positive regulation of transcription, DNA-templated;10.0;0.5159906454948852;0.673236334608363;8.141425192250265;1208.1179641469014;2.4745772039531437;0.04043462102441837;0.5417910051506925;[PID1, SPIB, AKT1, MEF2A, MEF2C, PADI2, ATF3, JUN, JAG1, JUP, FOS, MMP12, STAT4, ATAD2, PSMC6, PSMC2, LGR4, CCNT2, RUVBL2, BLM, FOXO1, NFKB1, CXCL10, CIITA, HHEX, PPP1R12A, E2F5, E2F7, POU2AF1, CCNH, TNFSF11, SFRP2, EGR1, EGR2, EGR3, CD28, BRCA2, CD3D, RGMA, IL1B, IL17A, CD86, CD80, CCNE1, HMGA1, INHBA, TCF4, HMGB2, ARHGEF10L, NUP62, MYOCD, PSRC1, ELF3, CREB5, TAF9, EGF, MAPK14, CD4, RAN, EHF, MYB, HOXA3, HOXA7, HOXA5, HOXB9, HOXB4, HOXB3, HOXB2, HOXB7, HOXB5, NUP85, PRDM16, NKX2-3, NFE2, FZD5, TGFB1I1, PAX5, PAX2, ENG, EPCAM, NR1H2, GTF2H1, PF4, PLXND1, TNF, CDH1, MEN1, MAP2K2, F2R, COPS5, MAFF, LBH, EMILIN1, RFC1, CHUK, SMARCD3, CEBPE, KLF1, KLF5, CHEK1, RPS6KA1, DPF3, SLC11A1, EBF1, FLT3LG, RUNX2, BEX1, NHLH2, BCL11B, IFNA2, PRL, RHOG, TLR4, TLR2, LILRB1, GRHL2, CAMK4, ARID4A, ARID4B, HOXA11, HOXA10, ADRB2, NLRP3, TGFB1, NR4A2, NFKBIA, NR4A1, SLC40A1, CKAP2, DCN, DNM2, DLL1, MEIS2, MEIS1, RBMX]
GO:0071773;cellular response to BMP stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;97.48528473772916;6.280566066213989;0.003262744749111514;0.6443087532925187;[TMEM100, SPINT1, SPINT2, ADAMTS12, RUNX2]
GO:0030308;negative regulation of cell growth;6.0;0.6913464685778243;0.6687935468790567;8.673012807464685;80.89021177018715;4.623782033182691;0.0027073225914839173;0.5595807407949613;[CDA, NRP1, SEMA5B, CDKN1A, ARHGAP4, TCHP, PPP2R1A, TNR, DCC, PSRC1, SFRP2, NDUFS3, FBP1, PAK1, TGFB1, CDKN2C, SEMA4B, INHBA, BCL6, SIPA1]
GO:0006958;complement activation, classical pathway;8.0;1.0;0.875;9.628524252492122;171.02669507306572;4.7081694254602375;0.005724109570062889;0.6157760033703056;[, IGHM, C1QA, CR2, CR1, IGHG1, IGKC, IGLV1-44, TRBC1, IGHD, IGHA1, IGKV3-20]
GO:0030948;negative regulation of vascular endothelial growth factor receptor signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;297.5747140953686;7.474488534686424;0.00995955788091634;0.7331650565203278;[HHEX, HGS, EMILIN1]
GO:0071897;DNA biosynthetic process;7.0;0.7090535922965819;0.7054461614054914;9.249034630787218;573.3007402310989;5.058574756385375;0.01918785983836615;0.609615113546532;[BRCA2, CTGF, RFC5, RFC3, RFC4, RFC1, RFC2, BLM, PCNA, POLD3, POLD1, RPA1, POLA1, POLA2, RAD50, POLE2, RPA3]
GO:0071774;response to fibroblast growth factor;5.0;0.9326813400603323;0.7565816818910864;9.474373572664863;24.053434438352202;6.221725566191056;8.050468039660755E-4;0.6084203466557585;[EGR3, TNC, NR4A1, CCL5, CCL2]
GO:0010811;positive regulation of cell-substrate adhesion;5.0;0.7980440201809971;0.6892630219514189;9.0094850440859;35.30989762708448;5.049685808968129;0.0011817904967337807;0.5484821789659555;[DOCK5, NRP1, EMILIN2, CCR7, EMILIN1, CD36, OLFM4, DNM2, CEACAM6, COL8A1, EPB41L5, FLNA, JUP, TEK]
GO:0070207;protein homotrimerization;7.0;1.0;0.8509193652572005;9.628524252492122;85.45061507946225;6.444869117505266;0.002859955186148837;0.6805102716434839;[ARG1, MGST1, MIF, TCL1A, EMILIN1, CD247]
GO:0050679;positive regulation of epithelial cell proliferation;6.0;0.7192862368539868;0.682763431017138;8.647694999480395;65.06748660449396;4.584116776790259;0.002177750219716307;0.5575522577384293;[NRP1, NRP2, HMGB2, TNFAIP3, CDH3, AKT1, GHSR, ARG1, PAX2, MMP12, AGTR1, C5AR1, TGFA, IQGAP3, CCL5, PLCG1, JUN, TGFB1, EGR3, CAV2, TNFSF12, LAMB1, NR4A1, LRG1, CXCL12, TEK]
GO:0035556;intracellular signal transduction;5.0;0.5140152493238541;0.5472486365228473;6.9204740513899115;23.17027026302992;2.4005655013542495;7.75488093814194E-4;0.41300604323788886;[AKT1, MEF2A, MEF2C, PRKAR1B, AGTR1, FPR1, FPR2, IQGAP3, PRKAR2B, SFN, LYN, ABCA1, JUN, HACE1, AZU1, ARHGAP6, ARHGAP4, DUSP1, GMIP, DUSP6, PTAFR, STAT4, DMD, PKN1, LGR4, CTGF, KCNH1, MSH6, MSH2, BLK, LY96, TNFRSF10B, BMX, CORO2A, NFKB1, LRRK2, TNFRSF1B, LCP2, IL2RG, CCL5, CCL2, FYN, E2F7, SH2B1, IL2RB, PTPN6, TNFSF11, PAQR3, MIF, BTC, BTK, RACGAP1, PAG1, CCR1, PTK2, RGL4, CD24, RGL1, BRCA2, CCR9, RAC2, CTSH, CCR7, CCR6, CD36, CCR5, SPTAN1, CCR2, LAT2, MC3R, IL1B, KIT, PCNA, GNAI2, PAK1, RAMP1, CD80, CELSR1, CCRL2, PDGFRB, DOK3, CARD11, CALCA, PSEN2, RASGRP4, SPTA1, GH1, TNFAIP3, GHR, GRM5, IRAK3, NDUFS4, BCL2A1, EPS8L1, EGF, MAPK14, TEK, CYFIP1, EPS8, STMN1, ADCY9, LGALS12, PRKCQ, PLCG1, PLK2, ITK, CDKN1A, NFAM1, PAX2, CIT, HBEGF, GSN, CCL20, CARD9, IL5RA, TNF, SLC8A1, FGF5, PYCARD, GRAP2, STK32B, MEN1, LHCGR, MAP2K2, DGKZ, NRBP1, RAB32, MELK, CALCRL, MAP2K6, DHCR24, BCL6, CNOT3, CSPG4, LAT, TREM1, CHUK, CX3CR1, RAB21, PLN, DNAJA3, EDNRB, PPP2R1A, CHEK1, RPS6KA1, PTGDR, SIK1, INPP5D, TP53BP2, CCR10, PRL, RALGPS2, MAP4K1, RHOG, RHOH, AVPR1A, VAV1, RAB33B, TLR8, TLR7, RHOU, SGK1, TLR4, PTGER2, CXCR5, CXCR4, CXCR6, CXCR1, CXCR2, PDPN, MLH1, CAMK4, SIPA1, SIRPG, ARHGDIA, ARHGDIB, TSC2, ATP1B1, CSF2RB, ADRB2, TGFB1, SELE, NFKBIA, ARHGAP30, JMY, DOCK5, MCTP1, CXCL1, TMEM100, BLNK, PTGIR, TGFBR3, ZAP70, NCAM1, TSHR]
GO:0019800;peptide cross-linking via chondroitin 4-sulfate glycosaminoglycan;9.0;1.0;0.896240625180289;9.628524252492122;433.4643727638907;7.9853141584524145;0.014507662463798891;0.8046099625986299;[SPOCK3, DCN]
GO:0033138;positive regulation of peptidyl-serine phosphorylation;10.0;0.9326813400603323;0.8815816818910864;9.59573442966913;778.6672313762616;5.152100814396198;0.026061291479152104;0.6787196871063318;[IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, TNF, TCL1A, AKT1, IFNA14, IFNA16, MIF, SFRP2, IFNG, IFNA10, PTGS2, PAK1, NTF3, IFNA21, TGFB1, CAV1]
GO:1902042;negative regulation of extrinsic apoptotic signaling pathway via death domain receptors;10.0;0.9326813400603323;0.8815816818910864;9.589303539338841;425.73912115989816;6.193554689224359;0.014249105244888325;0.731979686697602;[HMGB2, TNFAIP3, FASLG, TNFRSF10B, SFRP2]
GO:0016239;positive regulation of macroautophagy;8.0;0.7671156992804218;0.7585578496402109;9.242861771680136;266.06548500403863;5.666199763507158;0.008904972339694651;0.6647697194109919;[ADRB2, TSC2, DCN]
GO:0042662;negative regulation of mesodermal cell fate specification;10.0;0.8436909121759173;0.837086467948879;9.503361109538115;745.9340364622068;8.390779266560578;0.02496574090334154;0.8443458537639685;[SFRP2]
GO:1902203;negative regulation of hepatocyte growth factor receptor signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;187.41437209568753;9.777073627680469;0.006272590372058239;0.8509193652572005;[ADAMTS12]
GO:0009725;response to hormone;4.0;0.5257808277979137;0.5128904138989568;7.033269545535256;21.85620986101781;3.280298637494607;7.315076747364311E-4;0.41775462487096104;[CYFIP1, PID1, EDNRB, AKT1, PRKACB, PTGDR, MEF2C, CLDN4, POR, ADCY9, PRKAR1B, SIK1, ABCB4, SLC30A10, PRKAR2B, LYN, EGR1, EGR2, JUN, CDC6, SDC1, EZH2, ROBO2, CDKN1A, GABRB1, BRCA2, CTSS, CTSH, TIMP3, CCR7, TIMP1, ANXA1, DUSP1, ANXA3, ARG1, TACR3, AVPR1A, FOS, CEACAM1, IL1B, KIT, ENG, TLR2, PCNA, PTGER2, PTAFR, PTGS2, GNAI1, PAK1, CCL19, SORT1, SORBS1, RAMP1, TNC, TNF, CTGF, RUVBL2, MEN1, PDGFRB, GHSR, LHCGR, ADAM9, FOXO1, IGFBP7, CYC1, GAS2L1, EIF2B3, TGFB1, CAV1, DHCR24, INHBA, NFKB1, NR4A2, NR4A1, GH1, CXCL12, NASP, ALPL, HMGB2, GHR, ALAD, HHEX, UQCRFS1, GLP2R, TGFBR3, RETN, P2RY6, PLN, RBBP8, FYN, CSK, TSHR, CD4, TEK]
GO:1901509;regulation of endothelial tube morphogenesis;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;45.7200117395938;8.390779266560578;0.0015302076475850206;0.7522251544931926;[CXCL10, ADAMTS12]
GO:0048251;elastic fiber assembly;6.0;1.0;0.8231203125901445;9.628524252492122;39.541318973862396;7.474488534686424;0.0013234123611784638;0.7053660038532718;[MFAP4, EFEMP2, MYH11, EMILIN1]
GO:0071481;cellular response to X-ray;7.0;1.0;0.8509193652572005;9.628524252492122;60.39874674087868;7.379178354882098;0.0020214916980741903;0.728290889492758;[SFRP2, DNM2]
GO:0001558;regulation of cell growth;5.0;0.5833093054345528;0.5818956645781967;7.6590836060266145;26.25041167864861;3.793137346993279;8.785776550476476E-4;0.4842222321850823;[CDA, CYFIP1, CPNE5, KIAA1109, PPP2R1A, RPS6KA1, AKT1, SFRP2, AGTR1, PRKCQ, SFN, NRP1, CDKN1A, ARHGAP4, ESM1, AVPR1A, IL17RB, CEACAM1, SGK1, HBEGF, PAK1, CDKN2C, SIPA1, SEMA5B, CTGF, CXCL16, TNR, S100A8, IGFBP7, TGFB1, SYT2, CRIM1, INHBA, CXCL12, BCL6, TCHP, MYOCD, DCC, DNM2, PSRC1, NDUFS3, FBP1, TAF9, RAB21, SEMA4B]
GO:0051496;positive regulation of stress fiber assembly;11.0;1.0;0.9324289523296623;9.628524252492122;365.07497849775285;5.926926025970411;0.012218730984170163;0.735532224928036;[NRP1, ARHGEF10L, CTGF, PAK1, TPM1, NOX4]
GO:0050680;negative regulation of epithelial cell proliferation;6.0;0.7307253602413294;0.6884829927108091;8.690254613899192;65.19530579150691;4.989581884898423;0.0021820282128758306;0.5782877622231366;[PRL, PTPRK, BRCA2, PHB2, TNF, DUSP10, MEN1, MEF2C, TGFBR3, CEACAM1, SFRP2, CCL2, SFN, TGFB1, CAV2, CAV1]
GO:0050727;regulation of inflammatory response;6.0;0.5272636092234699;0.5867521172018795;7.400047131651798;31.586589572713706;3.8007227183825356;0.00105717472691369;0.517489449159909;[EDNRB, C3AR1, TNFSF11, IL1R1, IL1R2, BTK, AGTR1, ADAMTS12, PLA2G7, CD19, ELANE, LYN, BST1, CD28, FFAR2, CCR7, CCR2, ANXA1, FCER1G, IL17RB, PSMA6, HCK, IL1B, TLR10, TLR7, TLR6, TLR4, TLR2, C1QA, PTGS2, NT5E, IGKC, CCL18, CCL23, NLRP12, ZYX, IL17A, TNF, CDH5, IGHG1, GHSR, S100A8, SUCNR1, CALCRL, C5AR1, TNFRSF11A, IGLV1-44, NLRP3, SELE, NFKB1, NFKBIA, BCL6, IGKV3-20, MYD88, TNFAIP6, TNFAIP3, DUSP10, CR2, CR1, TNFRSF1B, XCL1, CNR1, CCL5, CCL4, MAPK14, CD6, TEK, FCGR2B]
GO:0034059;response to anoxia;5.0;0.8933024483968273;0.736892236059334;9.34084218004034;21.16160540946;8.67846133901236;7.082598888462125E-4;0.7340579283277371;[CTGF]
GO:0070278;extracellular matrix constituent secretion;6.0;0.8653626801206646;0.7558016526504768;9.377209824211215;23.0991473088411;8.67846133901236;7.731076725439974E-4;0.7669372290569613;[ENG, CTGF]
GO:0018146;keratan sulfate biosynthetic process;8.0;1.0;0.875;9.628524252492122;415.40755540718914;6.409777797693995;0.013903317036950667;0.7027963346592216;[OMD, OGN, ST3GAL6]
GO:0010667;negative regulation of cardiac muscle cell apoptotic process;10.0;1.0;0.9152410118609203;9.628524252492122;149.61163774803944;6.781341354126479;0.005007366873694588;0.7620391240755716;[MYOCD, SFRP2]
GO:0070318;positive regulation of G0 to G1 transition;7.0;1.0;0.8509193652572005;9.628524252492122;82.71654658760917;8.390779266560578;0.002768448374228408;0.7800242071602487;[CTGF]
GO:1905049;negative regulation of metallopeptidase activity;10.0;0.8933024483968273;0.861892236059334;9.59573442966913;499.6307270806722;7.9853141584524145;0.016722190796928726;0.8236103492792612;[TIMP3, TIMP1]
GO:0008285;negative regulation of cell proliferation;5.0;0.5619039856592722;0.5711930046905564;7.31175452450612;43.614270733588945;3.2818080717434612;0.0014597303911579066;0.4580728292695636;[SPINT2, PHB2, EPHB1, MEF2C, SFRP2, SPINT1, BTK, INPP5D, SFN, LYN, JUN, BCL11B, FZD5, CDC6, NOX4, CDKN1A, TNFRSF13B, TGFB1I1, PRL, PTPRK, BRCA2, CTLA4, CD33, HAVCR2, DUSP1, ARG1, PAWR, PDCD1LG2, CEACAM1, IL1B, TLR2, PTGS2, PAK1, GPNMB, PDPN, CCL23, CDKN2C, LILRB1, LILRB2, PODN, PKN1, CD86, CD80, SIRPG, TNF, CDH5, DACH1, MEN1, F2R, TPM1, TSC2, HGS, CD274, NACC2, IGFBP7, TGFB1, RARRES3, CAV2, CAV1, HMGA1, DHCR24, INHBA, BCL6, OGN, TNFAIP3, CXCL1, DUSP10, ADAMTS1, NUP62, PTGIR, MYOCD, TGFBR3, IFNG, XCL1, DLL1, CCL8, CCL2, ZNF503, CSK, E2F7, MEIS1, DNAJA3, CD9, PTPN6, MNDA, FCGR2B]
GO:0008284;positive regulation of cell proliferation;5.0;0.5587538620495764;0.5696179428857084;7.270369308343265;43.45254999490143;2.9881018846882994;0.0014543177435732513;0.44305268120482816;[PID1, TFRC, MYB, HOXA3, AKT1, PROK2, MEF2C, CLDN7, AGTR1, PRKCQ, ATF3, HHLA2, IQGAP3, PDGFD, PDGFC, NCKAP1L, PLCG1, ELANE, LYN, JUN, CDC6, CDKN1A, TIMP1, HLA-DPA1, HAVCR2, ANXA1, ARG1, FCRL3, PAX2, MMP12, HBEGF, PTAFR, KCNA5, PTGS2, HLA-DMB, EPCAM, NTF3, FLNA, CCL19, IL12RB1, IL12RB2, LRG1, HLA-DPB1, CHRM1, TNC, TNF, CTGF, FGF5, PYCARD, CDH3, F2R, MSH6, CD274, BLM, CALCRL, TNFRSF11A, CORO1A, NACC2, CXCL10, CXCL12, PTPRC, BCL6, FASLG, TNFSF13B, LBH, XCL1, CX3CR1, SMARCD3, LRP2, CCL5, CTHRC1, KLF5, DNAJA3, PTPN6, TCL1A, EDNRB, SKP2, ICOSLG, FLT3LG, MIF, RUNX2, BTC, SFRP2, TGFA, PKHD1, EGR1, EGR3, TNFSF12, PTK2, BST1, CD28, CD24, CD320, NRP1, NRP2, PRL, CD3E, ESM1, RAC2, CTSH, CCR2, SYK, RHOG, PDCD1LG2, AVPR1A, HCK, CEACAM6, IL1B, KIT, GNAI2, PAK1, CXCR2, LILRB2, CD40LG, CD86, CD80, SIRPG, IL6R, PDGFRB, GHSR, CCNE1, PRTN3, CARD11, C5AR1, LTBP3, DPP4, TGFB1, CAV2, NR4A1, LIN28A, HMGB2, TNFAIP3, LAMC2, CXCL5, MYOCD, GLP2R, MMP9, TGFBR3, ZAP70, IFNG, NDUFS4, LTF, DLL1, S1PR3, EGF, LAMB1, MAPK14, MEIS2, TSHR, CD4, CD6, TEK]
GO:0002063;chondrocyte development;4.0;0.8933024483968273;0.6966512241984136;9.474373572664863;32.15320660831846;6.943860283624253;0.001076138889173156;0.6051093378270707;[SFRP2, COL11A1, RUNX2, SULF2]
GO:0060548;negative regulation of cell death;5.0;0.5408746917014966;0.5606783577116685;7.270369308343265;41.94029430001592;2.875336421023895;0.0014037039064071987;0.4372858501489002;[PHB2, AKT1, PROK2, MEF2C, CLDN7, PRKCQ, ABCB4, SLC30A10, FIGNL1, SFN, NCKAP1L, BARD1, JUN, PLK2, AZU1, CDKN1A, CHL1, TIMP1, GPR37, ANXA1, DUSP1, ANXA5, SERPINB9, PAX2, PTGS2, UNG, GPNMB, NTF3, FLNA, CCL19, GABRA5, PF4, TNF, CTGF, CLEC5A, F2R, MSH2, BLM, CORO1A, FOXO1, WFS1, TNFRSF10C, TNFRSF10B, DHCR24, NFKB1, CXCL12, COPS5, BCL6, MYD88, LRRK2, FASLG, TNFRSF1B, ADAMTS20, CX3CR1, LRP1, NLRC4, CCL5, CCL2, FYN, TIE1, DNAJA3, IL2RB, SLC46A2, LGALS3, TCL1A, EDNRB, RPS6KA1, EPHB1, FLT3LG, MIF, BTC, POR, SFRP2, EPHA3, NAIP, PKHD1, EGR3, BCL11B, TNFSF14, PTK2, VNN1, CD28, NRP1, CTSH, CCR7, CCR5, FCER1G, HCK, CEACAM6, IL1B, KIT, GNAI2, CXCR2, PDPN, LILRB1, CD40LG, GRINA, COMP, ARHGDIA, PDGFRB, GHSR, C5AR1, PSEN2, CBX4, CAV1, NR4A2, NFKBIA, HMGB2, SLC40A1, TNFAIP3, NUP62, MYOCD, MMP9, NDUFS3, LTF, BCL2A1, TAF9, DLL1, HSPD1, TEK]
GO:0045669;positive regulation of osteoblast differentiation;6.0;0.9326813400603323;0.7894609826203107;9.56398573135455;169.86351353303945;5.734022359845919;0.005685178930713632;0.6163584827319739;[IL6R, CTHRC1, MEF2C, JAG1, RUNX2, SFRP2, LTF]
GO:0001890;placenta development;4.0;1.0;0.75;9.628524252492122;49.86610466882393;6.193554689224359;0.0016689736466849693;0.5667386748366816;[ABCB4, MAPK14, PTK2, DCN, E2F7]
GO:0045944;positive regulation of transcription by RNA polymerase II;11.0;0.5461734764479651;0.7055156905536448;8.363590748376499;1463.8556817380634;2.718315475161805;0.048993932283191266;0.5714437321440341;[EHF, PID1, SPIB, MYB, HOXA3, AKT1, HOXA7, HOXA5, MEF2A, MEF2C, HOXB9, HOXB4, HOXB3, HOXB2, HOXB7, ATF3, HOXB5, NKX2-3, JUN, JAG1, JUP, FZD5, PAX5, FOS, PAX2, MMP12, ENG, EPCAM, STAT4, NR1H2, ATAD2, GTF2H1, PSMC6, PSMC2, PF4, CCNT2, PLXND1, TNF, RUVBL2, MEN1, FOXO1, NFKB1, CXCL10, COPS5, MAFF, CIITA, HHEX, PPP1R12A, CHUK, CEBPE, E2F5, E2F7, KLF1, KLF5, POU2AF1, CCNH, RPS6KA1, TNFSF11, DPF3, SLC11A1, EBF1, FLT3LG, RUNX2, SFRP2, BEX1, NHLH2, EGR1, EGR2, EGR3, BCL11B, CD28, PRL, CD3D, RGMA, IL1B, TLR4, TLR2, LILRB1, GRHL2, IL17A, ARID4A, ARID4B, HOXA10, ADRB2, NLRP3, TGFB1, HMGA1, INHBA, NR4A2, NFKBIA, NR4A1, TCF4, HMGB2, SLC40A1, ARHGEF10L, MYOCD, CKAP2, DCN, ELF3, TAF9, DLL1, MAPK14, MEIS2, MEIS1, RBMX]
GO:0006029;proteoglycan metabolic process;6.0;0.7140352122741334;0.6801379187272112;9.057979394024509;96.66964063832829;5.825829909099042;0.0032354458751365986;0.6210535250702663;[COL11A1, ADAMTS12, NDST3, HS3ST3B1, SULF2]
GO:0002576;platelet degranulation;8.0;1.0;0.875;9.628524252492122;39.85546922145481;4.956792062075433;0.0013339266872485146;0.6284905765689417;[ORM1, SERPINA1, F13A1, LAMP2, TIMP3, CD36, TIMP1, ACTN1, ANXA5, ACTN4, F5, PECAM1, TLN1, VCL, STXBP2, FLNA, LYN, TGFB1, EGF, LHFPL2, PPBP, CD9, PF4]
GO:0007229;integrin-mediated signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.50247477320489;5.311165509025885;8.87013979980389E-4;0.5947335637161829;[NRP1, ITGAM, ITGB4, CTGF, ADAMTS1, ITGB6, FCER1G, SYK, VAV1, FGR, HCK, CEACAM1, ADAM9, ITGA7, TLN1, PTK2, ZYX, PLP1, LAT]
GO:0051385;response to mineralocorticoid;7.0;0.7980440201809971;0.7499413753476991;9.36615998802463;62.73690238121479;6.280566066213989;0.00209974766315278;0.6721078059595746;[CDKN1A, AVPR1A, FOS, CTGF]
GO:0071310;cellular response to organic substance;4.0;0.44223782556504454;0.47111891278252227;5.954033535830285;41.65973036582596;2.624021992742989;0.0013943136840210083;0.3841926067383783;[CYFIP1, PID1, TFRC, SPINT2, PHB2, MYB, AKT1, PRKACB, MEF2C, ADCY9, SPINT1, PRKAR1B, PADI2, ABCB4, FPR2, SLC30A10, ADAMTS12, IQGAP3, EPB41L5, KLRK1, PRKAR2B, PDGFD, PDGFC, ST3GAL6, PLCG1, LYN, ABCA1, JUN, JUP, CDC6, NOX4, EZH2, GABRB1, TIMP3, HLA-DPA1, HAVCR2, ANXA1, DUSP1, ARG1, FOS, PAX2, CCL13, PTAFR, PTGS2, CCL19, CCL18, IL12RB1, P2RY13, CCL23, GSN, CCL20, NR1H2, ZYX, PF4, TNC, CXCL13, TNF, SLC8A1, PYCARD, CDH1, RUVBL2, MEN1, TLE4, LHCGR, DGAT2, CD180, ADAM9, CD274, BLM, CALCRL, CORO1A, FOXO1, IGFBP7, MAP2K6, OSBPL7, DEFA4, DEFA1, NFKB1, CXCL10, CXCL11, SLC26A3, MCM7, LRRK2, TREM2, PTPN22, ALAD, CHUK, TNFRSF1B, XCL1, MCM2, CX3CR1, LRP1, CEBPE, P2RY6, CCL8, CCL7, CCL5, CCL4, CCL2, CCL1, FYN, CSK, KLF1, RAD51, KLF5, IMPDH2, PTPN6, FCGR2B, AQP9, TCL1A, EDNRB, TNFSF11, PTGDR, RUNX2, POR, KCNQ1, BTK, SIK1, EPHA3, STXBP2, EGR1, EGR2, EGR3, PPBP, ROBO2, NRP1, CTSS, CTSH, FFAR2, CTSG, CCR7, CD36, CCR5, MAP4K1, MME, PDCD1LG2, AVPR1A, CEACAM1, IL1B, KIT, TLR6, TLR4, TLR2, DTYMK, PTGER2, CXCR4, GNAI1, PAK1, CD58, LILRB1, LILRB2, SORBS1, NLRP12, CD68, RAMP1, IL18R1, IL17A, CD86, CD80, PDGFRB, GHSR, KMO, KIF16B, COL4A1, CALCA, CSF2RB, ADRB2, STAP1, NLRP3, GAS2L1, TGFB1, CAV1, INHBA, BSPRY, NR4A2, NFKBIA, NR4A1, LIN28A, ALPL, CXCL6, CXCL9, HMGB2, TNFAIP3, CXCL1, CXCL3, CXCL2, CXCL5, GHR, TMEM100, GRM5, PDE4B, GLP2R, DNM2, CHI3L1, COLEC12, MAPK14, TSHR, CD4, RBMX]
GO:0003429;growth plate cartilage chondrocyte morphogenesis;8.0;1.0;0.875;9.628524252492122;76.28302296905001;6.8867018697843045;0.002553124128510584;0.7271862538851576;[COL14A1, COL12A1, COL6A3]
GO:0019221;cytokine-mediated signaling pathway;6.0;0.6039883530135606;0.6251144890969248;7.604142487995313;26.50247477320489;3.309374901576116;8.87013979980389E-4;0.49236189895841853;[AKT1, FPR1, FLRT2, HLA-DQA1, HLA-DRB4, HLA-DRB1, CDKN1A, LRRC4, TIMP1, HLA-DPA1, ANXA1, FOS, FCER2, HLA-DQB1, CCL13, LRRC19, PTAFR, PTGS2, ALOX5, STAT4, CCL19, CCL18, IL12RB1, IL12RB2, CCL23, CCL20, HLA-DPB1, PF4, CSF3R, F13A1, IL5RA, CXCL13, TNF, PYCARD, IGHG1, IL13RA2, IFNA14, IFNA16, IFNA10, TNFRSF11A, FOXO1, TNFRSF17, IFNA21, TNFRSF10C, TNFRSF10B, NFKB1, CXCL10, CXCL11, CXCL12, BCL6, LCN2, HLA-DRA, MYD88, CIITA, ITGAM, FASLG, TNFSF13B, CHUK, TNFRSF1B, XCL1, CX3CR1, IL2RG, CCL8, CCL7, CCL5, CCL4, CCL2, CCL1, FYN, FCGR1B, IL2RB, PTPN6, TNFSF11, ACSL1, IL1R1, IL1R2, FLT3LG, MIF, INPP5D, CCR10, CCR1, EGR1, TNFSF14, TNFSF12, PPBP, SDC1, IFNA5, IFNA4, IFNA7, TNFRSF13B, IFNA2, IFNA8, CCR9, CCR7, CCR6, CD36, CCR5, CCR2, SYK, IL17RB, VAV1, HCK, CEACAM1, IL1B, KIT, RHOU, CXCR5, CXCR4, CXCR6, CXCR1, CXCR2, PODN, CD40LG, IL18R1, IL17A, CD86, CD80, IL18RAP, CCRL2, IL6R, PRTN3, CSF2RB, TGFB1, NFKBIA, CXCL6, CXCL9, CXCL1, CXCL3, CXCL2, CXCL5, GHR, LRRTM4, IRAK3, MMP9, DCN, IFNG, SAMHD1, NCAM1, CD4, LTBR]
GO:0001649;osteoblast differentiation;4.0;1.0;0.75;9.628524252492122;21.066225782797595;5.171903441692378;7.050676185779127E-4;0.5144913825262545;[TNC, FBL, AKT1, MEF2C, RUNX2, HSD17B4, GPNMB, FIGNL1, HSPE1, PSMC2, ALPL, RBMX, LGR4]
GO:0034446;substrate adhesion-dependent cell spreading;6.0;1.0;0.8231203125901445;9.628524252492122;56.23121614310476;6.088194173566533;0.0018820081995007299;0.63447084575632;[NRP1, LAMB1, TEK]
GO:0071799;cellular response to prostaglandin D stimulus;8.0;1.0;0.875;9.628524252492122;436.89110353785946;8.16763571524637;0.01462235205894615;0.7926932703116032;[TNC, PTGDR]
GO:0033630;positive regulation of cell adhesion mediated by integrin;5.0;0.9326813400603323;0.7565816818910864;9.4949928598676;34.61675044652454;6.943860283624253;0.0011585914843924019;0.6453503496879909;[SFRP2, SYK, CCL5, ADAM9, NCKAP1L, PTPN6, CXCL13]
GO:0030521;androgen receptor signaling pathway;8.0;0.8933024483968273;0.8216512241984136;9.446202695698167;54.01143535742291;5.948432231191374;0.0018077141342769656;0.6792031009335148;[TGFB1I1, CCNE1, RAN]
GO:0010596;negative regulation of endothelial cell migration;9.0;0.8436909121759173;0.8180860812682478;9.533214072687796;299.55593944109387;5.905872616772578;0.010025867710250715;0.6982672254532021;[MEF2C, TGFB1, JUP, CXCL13, DCN]
GO:0050732;negative regulation of peptidyl-tyrosine phosphorylation;10.0;0.7980440201809971;0.8142630219514189;9.446202695698167;781.0212663083519;5.926926025970411;0.02614007890983527;0.7183442844592942;[PPP2R1A, NTF3, CAV1, SFRP2, PTPN6]
GO:0061185;negative regulation of dermatome development;7.0;1.0;0.8509193652572005;9.628524252492122;121.41107568444949;9.777073627680469;0.004063519440284355;0.8509193652572005;[SFRP2]
GO:0022617;extracellular matrix disassembly;5.0;0.8653626801206646;0.7229223519212526;9.377209824211215;37.09213040667776;5.69953618377475;0.0012414402239614005;0.581715557354699;[MMP8, MMP9, CTSS, MMP12, CTSG, TIMP1, ELANE]
GO:0048704;embryonic skeletal system morphogenesis;5.0;0.8653626801206646;0.7229223519212526;9.377209824211215;45.48774390093071;5.346256828837156;0.0015224338520524504;0.5636488347140203;[COL11A1, HOXA11, HOXA3, HOXA7, HOXA5, HOXA4, PAX5, GRHL2, RUNX2, HOXB4, HOXB3, HOXB2, HOXB7, DSCAML1, HOXB6, HOXB5]
GO:0030514;negative regulation of BMP signaling pathway;12.0;0.8259837884571596;0.8611122068187244;9.4949928598676;599.3292772798114;5.905872616772578;0.02005901154922404;0.7501469128630576;[LRP2, SFRP2]
GO:0007517;muscle organ development;4.0;0.7763722522362496;0.6381861261181248;8.753055515138222;27.682183388997124;5.085725745451326;9.264977656821302E-4;0.5100842511328143;[TAGLN, SGCE, BASP1, DMD, MEF2A, MEF2C, EGR3, CXCL10, ITGA7, COL6A3, HBEGF]
GO:0071300;cellular response to retinoic acid;6.0;1.0;0.8231203125901445;9.628524252492122;200.602279209425;5.54296712308321;0.006713977754809188;0.606587909038952;[LYN, ABCA1, TNC, PHB2, PAX2, MYB, EPHA3]
GO:0050867;positive regulation of cell activation;5.0;0.5557027117453593;0.5680923677336;7.431299675155902;42.06625563378019;3.805811787890007;0.0014079197188904481;0.48487040368196277;[, TFRC, MYB, TRBC1, RPS6KA1, AKT1, TNFSF11, ICOSLG, MEF2C, FLT3LG, MIF, BTK, PRKCQ, HHLA2, KLRK1, INPP5D, NCKAP1L, IGHA1, ICOS, LYN, EGR3, TNFSF14, BST1, VNN1, CD28, CD24, CD320, IGHM, CDKN1A, CD3E, CTLA4, CCR7, CCR2, HLA-DPA1, HAVCR2, ANXA1, FCER1G, SYK, FCRL3, PDCD1LG2, VAV1, IL1B, IGHD, TLR6, TLR4, PTAFR, UNG, PAK1, HLA-DMB, IGKC, PDPN, CCL19, IL12RB1, LILRB1, LILRB2, MLH1, CD40LG, HLA-DPB1, CD86, CD83, CD80, SIRPG, CTGF, PYCARD, IGHG1, GRAP2, IL6R, CD177, PDGFRB, MSH6, MSH2, CARD11, CD274, BLM, CORO1A, DPP4, BTLA, STAP1, NLRP3, TGFB1, CAV1, PTPRC, BCL6, ITGAM, LRRK2, SIRPB1, TNFSF13B, DUSP10, FGR, ZAP70, IFNG, LCK, XCL1, HSPD1, CCL5, CCL2, FYN, CSK, CD2, CD4, CD6, DNAJA3, PTPN6]
GO:0032496;response to lipopolysaccharide;5.0;0.8933024483968273;0.736892236059334;9.446202695698167;64.414971589946;4.086714173356409;0.002155911129404774;0.4992357647380114;[CD86, CD80, CXCL13, PYCARD, EDNRB, GHSR, CD96, MEF2C, SLC11A1, CD180, F2R, KMO, SLPI, ADAM9, S100A8, CD274, ABCB4, C5AR1, MGST1, LY96, CSF2RB, TNFRSF11A, KLRK1, STAP1, NLRP3, S100A14, ELANE, ABCA1, JUN, DEFA4, TNFRSF10C, TNFRSF10B, DEFA1, PPBP, SELE, NFKB1, CXCL10, CXCL11, ALPL, CXCL6, CXCL9, HMGB2, TNFAIP3, CXCL1, TREM2, FASLG, PTPN22, CXCL3, CXCL2, CXCL5, ALAD, DUSP10, PDE4B, CTSG, CCR7, CD36, CCR5, HAVCR2, PTGIR, CHUK, ARG1, IRAK3, PDCD1LG2, FOS, TNFRSF1B, DCN, IL1B, TLR4, CX3CR1, CEBPE, PTGER2, PTGS2, CNR1, CCL2, IL12RB2, GCH1, CCL20, NR1H2, LILRB1, LILRB2, MAPK14, CD6, LTBR, PF4]
GO:0030199;collagen fibril organization;5.0;1.0;0.7902410118609202;9.628524252492122;53.964823970696955;5.9928839937622085;0.0018061540931107725;0.5967173779995258;[COL14A1, COL11A1, COL12A1, SFRP2]
GO:0050866;negative regulation of cell activation;5.0;0.568528391149758;0.5745052074357992;7.549082710812286;42.2279763724677;4.60092389510664;0.0014133323664751037;0.5255324738215157;[CD86, CD80, SLA2, LGALS3, IL13RA2, LAG3, BTK, CD274, INPP5D, PAG1, LYN, TGFB1, INHBA, BCL6, CD200, TNFRSF13B, IFNA2, TNFAIP3, PTPN22, CTLA4, EMILIN1, CCR2, HAVCR2, ANXA1, ARG1, PAWR, PDCD1LG2, CEACAM1, BANK1, XCL1, BPI, GPNMB, CNR1, LILRB1, LILRB2, CD9, PTPN6, MNDA, PKN1, FCGR2B]
GO:0030512;negative regulation of transforming growth factor beta receptor signaling pathway;8.0;0.8933024483968273;0.8216512241984136;9.537552474286395;374.7458266990886;5.54296712308321;0.012542405570270547;0.6584675964488075;[TGFB1I1, PRDM16, EMILIN1, TGFB1, CAV2, CAV1, DNM2, TGFBR3]
GO:0071305;cellular response to vitamin D;8.0;1.0;0.875;9.628524252492122;396.2010793692189;7.379178354882098;0.013260493568666019;0.7523715242355574;[TNC]
GO:2001113;negative regulation of cellular response to hepatocyte growth factor stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;110.85348918024057;9.777073627680469;0.0037101665211994655;0.8231203125901445;[ADAMTS12]
GO:0030511;positive regulation of transforming growth factor beta receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;345.4564576873422;6.518977089658987;0.011562116748168153;0.7083807915285978;[MYOCD, TGFB1I1, TGFBR3, LRG1, MEN1]
GO:0018108;peptidyl-tyrosine phosphorylation;9.0;0.811012628672052;0.801746939516315;9.414950152194063;338.33129968976414;4.530049555519983;0.011323644122215096;0.627907570118429;[IL5RA, SLA2, FGF5, EFEMP1, GRAP2, EPHB1, PDGFRB, MAP2K2, BTC, MELK, BTK, EPHA3, BLK, CSF2RB, MAP2K6, LYN, BMX, CLK4, PTK2, CLK1, ITK, GHR, SYK, FGR, ZAP70, HCK, LCK, KIT, HBEGF, FYN, CSK, IL12RB2, EGF, TIE1, WEE1, PTPN6, TEK]
GO:1902230;negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage;10.0;0.9326813400603323;0.8815816818910864;9.596775554177542;831.2496569477559;6.409777797693995;0.02782117794191935;0.7430373465201421;[TAF9, MIF, CXCL12, SFRP2]
GO:0032092;positive regulation of protein binding;5.0;0.7090535922965819;0.6447678080092112;8.529911963824013;32.707776742429765;5.311165509025885;0.0010946998524811438;0.5618542629869587;[NRP1, PLXND1, LRRK2, MEN1, MEF2C, MMP9, LRP1, EPB41L5, CTHRC1, PLK2, CAV1, RAN]
GO:0007173;epidermal growth factor receptor signaling pathway;9.0;0.7763722522362496;0.7844267512984139;9.040737587590003;32.38857880465376;5.788089581116195;0.0010840165847632744;0.6922437955322635;[TGFA, SLC30A10, EPS8, EFEMP1, REPS2, AKT1, PLCG1, TGFB1, EGF, GAB1, PTK2, BTC, KIF16B, HBEGF]
GO:2000041;negative regulation of planar cell polarity pathway involved in axis elongation;10.0;1.0;0.9152410118609203;9.628524252492122;455.7071039869726;9.083926447120524;0.015252106660676964;0.8797934328124444;[SFRP2]
GO:0006366;transcription by RNA polymerase II;10.0;0.6039883530135606;0.7172351883677006;8.613793447804714;583.8786478812184;3.2909128387363804;0.01954189288791682;0.5835384474769965;[EHF, CCNH, SPIB, MYB, HOXA7, HOXA5, MEF2A, MEF2C, HOXB3, HOXB2, HOXB7, ATF3, HOXB5, NHLH2, EGR1, EGR2, JUN, BCL11B, TGFB1I1, PAX5, FOS, PAX2, FLNA, GTF2H1, GRHL2, CCNT2, ARID4A, HOXA10, C5AR1, HMGA1, NFKB1, COPS5, MAFF, MYOCD, ELF3, CREB5, CEBPE, TAF9, POLR2E, POLR2I, POLR2J, POLR2K, POLR2L, MEIS2, MEIS1, KLF5, POU2AF1, RBMX]
GO:0008543;fibroblast growth factor receptor signaling pathway;8.0;0.7090535922965819;0.729526796148291;8.567652291806858;31.002284443533863;5.395046993006588;0.0010376185600805164;0.6509029541176994;[CTGF, FGF5, FLRT2, POLR2E, POLR2I, POLR2J, POLR2K, POLR2L, KIF16B, ESRP1]
GO:0045600;positive regulation of fat cell differentiation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;114.26328322821418;5.71663061713405;0.00382428925936973;0.6154690682008903;[PTGS2, PRDM16, AKT1, TMEM64, MAPK14, KLF5, SFRP2]
GO:0006367;transcription initiation from RNA polymerase II promoter;9.0;1.0;0.896240625180289;9.628524252492122;477.15162764714074;4.629579150867016;0.015969835568764485;0.6329975182530758;[CCNH, NR3C2, CTGF, NRBP1, RUNX2, MAZ, NR4A2, NR4A1, TCF4, CDKN1A, MED23, TAF9, POLR2E, POLR2I, POLR2J, POLR2K, POLR2L, NR1H2, GTF2H1]
GO:0060447;bud outgrowth involved in lung branching;6.0;1.0;0.8231203125901445;9.628524252492122;21.218694376440094;8.67846133901236;7.101706051943016E-4;0.7669372290569613;[TNC]
GO:0009749;response to glucose;7.0;0.8933024483968273;0.7975705894556142;9.405380701177911;32.95598622603122;4.917261223318797;0.001103007200523252;0.6023883328937558;[SLC8A1, CTGF, MEN1, RMI1, PAX2, IL1B, EGR1, EIF2B3, TGFB1, LIN28A, NOX4]
GO:0048048;embryonic eye morphogenesis;6.0;0.9326813400603323;0.7894609826203107;9.510741216835738;49.04309196241861;6.686031174322154;0.001641428152064931;0.665044257777226;[EFEMP1, FZD5, MFAP2]
GO:0051045;negative regulation of membrane protein ectodomain proteolysis;9.0;1.0;0.896240625180289;9.628524252492122;966.2736676900156;7.697632086000634;0.032340310067742455;0.7898978880348613;[TIMP3, TIMP1]
GO:0043154;negative regulation of cysteine-type endopeptidase activity involved in apoptotic process;12.0;0.8653626801206646;0.8808016526504769;9.556203590912496;734.4861809891323;5.277263957350204;0.024582591483058774;0.7179998367869053;[RPS6KA1, AKT1, SERPINB9, TNFRSF1B, MMP9, PAX2, POR, SFRP2, NAIP, NLRC4, PTGS2, SFN, TNFSF14, TNFRSF10C, TNFRSF10B, DHCR24]
GO:0042340;keratan sulfate catabolic process;8.0;1.0;0.875;9.628524252492122;411.1022627208988;7.292166977892469;0.013759222765252392;0.747921758369865;[OGN, OMD]
GO:0016055;Wnt signaling pathway;7.0;0.5916390046238794;0.6467388675691402;7.647522783625538;28.581916314885376;4.0633408221711;9.566110170045473E-4;0.558718803867703;[CELSR1, CDH3, AP2M1, TLE4, HOXB9, SFRP2, CCNE1, PFN1, APCDD1, FZD5, NR4A2, VANGL1, SDC1, CD24, CDK14, LRRK2, TGFB1I1, HHEX, AES, CTHRC1, EGF, TMEM64, LGR4]
GO:0016331;morphogenesis of embryonic epithelium;5.0;0.7369933605727446;0.6587376921472925;8.424551448166186;31.670476732859363;6.599019797332524;0.0010599823546702226;0.6277151911823093;[EPB41L5, HHEX, TGFB1I1, PAX2]
GO:0010975;regulation of neuron projection development;8.0;0.5673924682959377;0.6586962341479689;8.404748820870006;84.29486529122617;3.652390236786265;0.0028212732808438556;0.5617834065627654;[CYFIP1, CPNE5, AKT1, MEF2C, PAQR3, SFRP2, EPHA3, SDC2, LYN, PLK2, PTK2, EZH2, ITM2C, ROBO2, NRP1, ARHGAP4, RGMA, PAK1, SCARB2, SEMA5B, PLXND1, FMR1, ARHGDIA, TNR, SYT2, CXCL12, LRRK2, DCC, DNM2, NLGN1, LRP1, RAB21, CNR1, FYN, LINGO1, SEMA4B]
GO:0050910;detection of mechanical stimulus involved in sensory perception of sound;6.0;1.0;0.8231203125901445;9.628524252492122;83.9288867027761;7.379178354882098;0.0028090243068477775;0.7004918368257019;[COL11A1, KIT]
GO:0051603;proteolysis involved in cellular protein catabolic process;6.0;0.6519675769143192;0.6491041010473041;8.270400768338927;49.64990487012002;3.4509241545253704;0.001661737633989536;0.49960073433695684;[, ADAMTS12, HACE1, TGFB1I1, PSMA5, PSMA6, PSMA3, PSMA4, PSMA2, USP9Y, PSMC6, PSMC2, WFS1, HM13, RNF24, SKP2, CTSS, CTSH, RANBP2, RANBP1, PSMD14, TNFAIP3]
GO:0030500;regulation of bone mineralization;6.0;0.8259837884571596;0.7361122068187242;9.405380701177911;42.16292605820722;5.572381008289503;0.0014111551909982874;0.6080921364962873;[ADRB2, SLC8A1, ANKH, CCR1, MEF2C, TGFB1, OMD, MGP, LTF]
GO:0033690;positive regulation of osteoblast proliferation;6.0;1.0;0.8231203125901445;9.628524252492122;63.05258358394898;7.379178354882098;0.0021103132289136558;0.7004918368257019;[LTF, CTHRC1]
GO:1904027;negative regulation of collagen fibril organization;7.0;1.0;0.8509193652572005;9.628524252492122;172.06691781788473;9.083926447120524;0.0057589248891922904;0.8154717862087246;[EMILIN1]
GO:0007186;G-protein coupled receptor signaling pathway;5.0;0.5508212674310002;0.5656516455764204;7.20077601654407;23.17027026302992;2.605416804911955;7.75488093814194E-4;0.4234821484283897;[MRGPRF, EDNRB, GPR171, C3AR1, AKT1, PROK2, PRKACB, PTGDR, TAS2R10, TAS2R13, TAAR2, TRHR, ADCY9, SFRP2, AGTR1, FPR1, FPR3, FPR2, OR7D2, CCR10, CCR1, ABCA1, GPR15, FZD5, OR2J2, AZU1, NMBR, PPBP, MARCO, PNOC, OR7C2, GPR18, GPR19, GPR25, GABRB1, GRIK3, CD3E, CCR9, RAC2, FFAR2, CCR7, CCR6, CCR5, CCR2, GPR37, ANXA1, RHOG, GPBAR1, TACR3, AGTRAP, PTH2R, AVPR1A, SORCS3, VAV1, MC3R, CCL13, PTGER2, PTAFR, CXCR5, CXCR4, CXCR6, GNAI1, GNAI2, FGD3, FGD4, CXCR1, CXCR2, FLNA, CCL19, GABRE, CCL18, GPR157, P2RY13, GABBR1, CCL23, SORT1, GABRA5, CCL20, P2RY14, GPR6, RAMP1, LGR4, F2RL3, PF4, CHRM2, CHRM1, CELSR1, CXCL13, CXCL16, RGS1, CCRL2, PDGFRB, CD97, GHSR, LHCGR, F2R, NPY1R, DGKZ, SPNS1, OR2C3, CALCA, SUCNR1, CALCRL, GPR87, C5AR1, GPR85, GPR84, ADRB2, GPR82, HRH4, DRD4, HTR1E, CAV1, GPR98, CXCL10, CXCL11, CXCL12, GNB2, OR7E24, TAS2R7, CXCL6, CXCL9, OR1G1, CXCL1, CXCL3, CXCL2, CXCL5, GRM5, PDE4B, PTGIR, GLP2R, OR2H1, XCL1, CX3CR1, LRP1, OR1E1, P2RY6, CCL8, PLN, CCL7, CNR1, P2RY2, OR2W1, CCL5, CCL4, CCL2, S1PR3, OR12D3, CCL1, S1PR5, TSHR, OR11A1, PTPN6]
GO:0060394;negative regulation of pathway-restricted SMAD protein phosphorylation;10.0;1.0;0.9152410118609203;9.628524252492122;1014.8354762495777;7.379178354882098;0.03396563009744072;0.7926125360964777;[EMILIN1]
GO:0090263;positive regulation of canonical Wnt signaling pathway;8.0;0.8259837884571596;0.7879918942285797;9.417215158824915;236.52854047757646;5.244474134527214;0.007916397387918217;0.6432026511327102;[LRRK2, RUVBL1, JUP, EGF, CAV1, NFKB1, SULF2, SFRP2, LGR4, NAIP]
GO:0043312;neutrophil degranulation;9.0;1.0;0.896240625180289;9.628524252492122;132.80263134205524;3.603287523778533;0.004444784556409926;0.5805129167163294;[CDA, CYFIP1, ABCA13, C3AR1, RNASE3, RNASE2, BIN2, PADI2, FPR1, FPR2, NCKAP1L, ELANE, JUP, AZU1, LYZ, TCN1, ARHGAP9, SIGLEC9, SERPINA1, PYGL, OLR1, ANXA3, ARG1, NFAM1, PSMA5, PSMA2, SERPINB10, PTAFR, ALOX5, GSN, LRG1, SLCO4C1, PSMC2, SIGLEC5, HP, APEH, PYCARD, CLEC5A, LAMP2, CD177, OLFM4, CLEC4D, SLC27A2, S100A8, BRI3, HVCN1, GPR84, ATP8B4, DEFA4, DEFA1, NFKB1, PTPRC, LCN2, ITGAM, FCAR, ALAD, FCGR3B, DSP, CR1, NDUFC2, TNFRSF1B, PECAM1, BPI, ACPP, TTR, FCGR2A, P2RX1, IMPDH2, PTPN6, MNDA, FOLR3, LGALS3, ANPEP, SLC11A1, MIF, CHIT1, SLPI, CRISPLD2, STXBP2, MGST1, PRG2, NBEAL2, PPBP, BST1, VNN1, ORM1, CTSS, GLIPR1, CTSH, CTSG, CD36, SPTAN1, CAMP, CD33, CCT2, FCER1G, MME, RHOG, CEACAM1, CEACAM6, TLR2, LILRA3, CXCR1, CXCR2, CD58, CCT8, LILRB2, LILRB3, QPCT, CD68, CD97, CHRNB4, CD93, OSCAR, DOK3, PRTN3, VCL, PSMD14, C5AR1, MGAM, MS4A3, TNFAIP6, CRISP3, CXCL1, SIRPB1, HK3, MMP8, MMP9, FGR, CHI3L1, LTF, CLEC12A, RETN, MAPK14, S100P, PTX3]
GO:0090141;positive regulation of mitochondrial fission;8.0;1.0;0.875;9.628524252492122;158.83836540067767;7.069023426578259;0.005316177144712613;0.7365101867784198;[DCN]
GO:0038063;collagen-activated tyrosine kinase receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;57.50475921673876;7.474488534686424;0.0019246325400609058;0.7572456912631272;[SYK, COL4A1]
GO:0043434;response to peptide hormone;6.0;0.6696747006330769;0.657957662906683;8.712233520617966;71.32532737153224;4.149452513989832;0.0023871945184980284;0.5353235071248601;[CYFIP1, CTGF, EDNRB, AKT1, PRKACB, MEN1, GHSR, LHCGR, POR, ADCY9, PRKAR1B, ABCB4, SLC30A10, FOXO1, PRKAR2B, CYC1, LYN, EGR1, EGR2, EIF2B3, TGFB1, CAV1, CDC6, NFKB1, NR4A2, NR4A1, CXCL12, HHEX, TIMP1, ANXA1, ARG1, GLP2R, TGFBR3, CEACAM1, IL1B, TLR2, RETN, PTGS2, GNAI1, PAK1, PLN, FYN, CSK, SORT1, SORBS1, TSHR, TEK]
GO:0046426;negative regulation of JAK-STAT cascade;9.0;0.9326813400603323;0.8625812952104552;9.577230958104572;286.97803335492995;5.845247994956144;0.009604896512927369;0.6951668794741764;[LRRC19, CAV1, LRRC4, PODN, DCN, FLRT2, HGS, PPP2R1A, LRRTM4]
GO:0048208;COPII vesicle coating;6.0;1.0;0.8231203125901445;9.628524252492122;62.43707956725794;5.6339389012889365;0.0020897128633926582;0.6112402100070131;[SERPINA1, TGFA, F5]
GO:0042744;hydrogen peroxide catabolic process;6.0;0.9326813400603323;0.7894609826203107;9.55953138100517;235.80375524332874;6.481236761676141;0.007892139478392308;0.6545710619905948;[PXDN]
GO:0030855;epithelial cell differentiation;4.0;0.5489353771682173;0.5244676885841086;6.961296045910167;21.066225782797595;4.034070439870987;7.050676185779127E-4;0.45630254989846264;[EHF, LGALS3, BASP1, AKT1, HOXA5, MEN1, MEF2C, COL4A1, ADAM9, HOXB5, ST14, JUN, TGFB1, JAG1, CD24, TGFB1I1, SLC7A11, TMEM100, HHEX, LBH, DSP, ANXA1, PAX2, ELF3, TAGLN, PCNA, E2F7, USH2A, GRHL2]
GO:0043280;positive regulation of cysteine-type endopeptidase activity involved in apoptotic process;12.0;0.811012628672052;0.8536266269261705;9.556203590912496;733.386781063286;4.956792062075433;0.024545795556936395;0.7016108891590862;[FASLG, TNF, CTGF, PYCARD, CTSH, F2R, LCK, S100A8, NLRC4, HSPD1, NLRP3, GSN, TNFRSF10B, HSPE1, NLRP12, P2RX1]
GO:0030579;ubiquitin-dependent SMAD protein catabolic process;9.0;1.0;0.896240625180289;9.628524252492122;157.5507831317809;7.9853141584524145;0.005273082924921447;0.8046099625986299;[TGFB1I1]
GO:0010629;negative regulation of gene expression;6.0;0.471430776349301;0.558835700764795;6.738152494595957;59.04642522059629;2.349334787147576;0.001976230713800692;0.44326540286011196;[EHMT2, SLA2, AKT1, MEF2A, MEF2C, ATF3, IQGAP3, JUN, PKIG, EZH2, MMP12, BTAF1, FLNA, LGR4, GMNN, CTGF, FOXO1, NFKB1, CIITA, LRRK2, FASLG, HHEX, FYN, E2F7, EIF3E, UXT, MIF, SFRP2, KCNQ1, NAIP, PCBP3, CCR1, EGR1, MSR1, CD28, PTPRK, CD3E, CD36, BANK1, IL1B, CCNE1, CALCA, CAV1, HMGA1, MXD1, HMGB2, MYOCD, ELF3, FBP1, PHB2, MYB, HOXA7, HOXB4, HOXB3, PRDM16, ELANE, BARD1, NDFIP2, CDKN1A, HAVCR2, PAWR, PAX5, PAX2, AES, ENG, NR1H2, FMR1, TNF, DACH1, MEN1, TLE4, MAP2K2, NACC2, WFS1, LSM5, LSM3, BCL6, CNOT3, PTPN22, EMILIN1, CR1, RFC1, PTBP2, XCL1, NLRC4, RBBP8, ZNF503, KLF8, KLF5, DNAJA3, ZNF608, EDNRB, PPP2R1A, MAGOH, DPF3, IL1R2, RUNX2, BCL11A, IFNA2, XPO1, MLH1, ARID4A, CHCHD3, BASP1, TGFB1, CBX4, EIF2S1, NR4A2, LIN28A, CREBZF, IFNG, PFDN5, MEIS2, RBMX]
GO:0006888;ER to Golgi vesicle-mediated transport;6.0;1.0;0.8231203125901445;9.628524252492122;49.13394272044514;4.493869898942481;0.001644468845175705;0.5529370282083849;[, NRBP1, COPB2, TGFA, SPTA1, SERPINA1, SPTAN1, TMED6, F5, RAB33B, GOPC]
GO:0031668;cellular response to extracellular stimulus;4.0;0.5452700253111464;0.5226350126555732;7.377232453885626;45.163559484697416;4.334655917158676;0.0015115836913881548;0.47167450518560927;[EHMT2, TNC, LAMP2, SKP2, SFRP2, SIK1, ATF3, SEH1L, ABCB4, FOXO1, GAS2L1, LYN, JUN, EIF2S1, NR4A2, CDKN1A, PLEKHF1, LRRK2, ASGR1, UPP1, AVPR1A, FOS, AES, PTGS2, FYN, SIPA1]
GO:0003417;growth plate cartilage development;6.0;1.0;0.8231203125901445;9.628524252492122;33.90475965706645;8.16763571524637;0.001134761793419349;0.7408135829017477;[COMP]
GO:0010628;positive regulation of gene expression;6.0;0.4705935272257725;0.5584170762030307;6.666693530613812;58.797024432214236;2.2471302570788807;0.001967883493859682;0.43803865843940215;[PID1, SPIB, AKT1, MEF2A, MEF2C, PADI2, ATF3, IQGAP3, JUN, JAG1, JUP, AZU1, FOS, MMP12, PTAFR, STAT4, ATAD2, PSMC6, PSMC2, LGR4, CCNT2, CTGF, RUVBL2, PKP3, BLM, FOXO1, NFKB1, CXCL10, MYD88, CIITA, HHEX, PPP1R12A, CCL5, E2F5, E2F7, POU2AF1, EIF3E, EIF3D, CCNH, TNFSF11, SFRP2, EGR1, EGR2, EGR3, CD28, BRCA2, CD3E, CD3D, CTSH, CD36, RGMA, IL1B, KIT, IL17A, CD86, CD80, ACTG2, CCNE1, CAV1, HMGA1, INHBA, TCF4, HMGB2, ARHGEF10L, NUP62, MYOCD, ACTA2, PSRC1, ELF3, CREB5, TAF9, EGF, MAPK14, CD4, RAN, EHF, MYB, HOXA3, HOXA7, HOXA5, HOXB9, HOXB4, HOXB3, HOXB2, HOXB7, HOXB5, NUP85, PRDM16, NKX2-3, NFE2, FZD5, TGFB1I1, PAWR, SERPINB9, PAX5, PAX2, ENG, EPCAM, GSN, NR1H2, GTF2H1, PLP1, PF4, PLXND1, FMR1, TNC, TNF, CDH3, CDH1, MEN1, MAP2K2, F2R, ADAM2, COPS5, MAFF, PTPN22, LBH, EMILIN1, RFC1, CHUK, SMARCD3, CEBPE, POLR2E, POLR2K, POLR2L, KLF1, KLF5, CHEK1, RPS6KA1, DPF3, SLC11A1, EBF1, FLT3LG, RUNX2, BEX1, NHLH2, BCL11B, IFNA2, PRL, RHOG, TLR6, TLR4, TLR2, LILRB1, GRHL2, CAMK4, ARID4A, ARID4B, HOXA11, HOXA10, HGS, ADRB2, STAP1, NLRP3, TGFB1, NR4A2, NFKBIA, NR4A1, LIN28A, SLC40A1, CKAP2, DCN, DNM2, IFNG, DLL1, MEIS2, MEIS1, RBMX]
GO:0035987;endodermal cell differentiation;4.0;1.0;0.75;9.628524252492122;21.066225782797595;6.444869117505266;7.050676185779127E-4;0.5795909063862833;[LAMB3, COL11A1, LAMA3, COL12A1, COL8A1, ITGA7, LAMB1, INHBA, MMP8, MMP9]
GO:0032355;response to estradiol;5.0;0.9326813400603323;0.7565816818910864;9.523163736834295;74.25476231829794;4.940791720728991;0.0024852400698459885;0.542913330229313;[BRCA2, CTGF, RUVBL2, PDGFRB, GHSR, ANXA1, DUSP1, TACR3, IL1B, PCNA, ABCB4, PTGS2, RBBP8, TGFB1, GH1, CD4, EZH2]
GO:0010469;regulation of signaling receptor activity;6.0;0.5916390046238794;0.6189398149020842;7.95454781892045;48.619731222684926;3.470798340732454;0.0016272586491059737;0.5006171011438312;[CXCL13, TNF, CTGF, CXCL16, FGF5, EFEMP1, VSTM1, TNFSF11, MEF2C, IFNA14, IFNA16, FLT3LG, MIF, BTC, SFRP2, IFNA10, CALCA, TGFA, ADRB2, PDGFD, PDGFC, IFNA21, TGFB1, JAG1, TNFSF14, TNFSF12, INHBA, PPBP, GH1, CXCL10, CXCL11, CXCL12, PNOC, OGN, CD320, IFNA5, IFNA4, NRP1, CXCL6, IFNA7, CXCL9, IFNA2, CXCL1, FASLG, PRL, CXCL3, IFNA8, CXCL2, CXCL5, TNFSF13B, TIMP1, IFNG, IL1B, XCL1, HBEGF, CCL13, NLGN1, CLEC12B, RETN, CCL8, TTR, GPNMB, CCL7, CCL5, CCL4, NTF3, CCL2, CCL1, CCL19, CCL18, CCL23, EGF, CCL20, CD40LG, CMTM2, FCGR2B, PF4, IL17A]
GO:0048050;post-embryonic eye morphogenesis;6.0;0.9326813400603323;0.7894609826203107;9.510741216835738;48.05391351479887;7.9853141584524145;0.0016083212396259044;0.7314896500084853;[EFEMP1, MFAP2]
GO:0030336;negative regulation of cell migration;7.0;0.5846489169746516;0.6432438237445264;8.20713857156096;158.04059951544355;4.3090134865453384;0.00528947663847651;0.5712825153487487;[CXCL13, DACH1, ARHGDIB, HOXA7, MEF2C, TPM1, MIF, SFRP2, PADI2, VCL, TACSTD2, KLRK1, STAP1, TGFB1, JAG1, JUP, CXCL12, GPR18, PTPRR, MCTP1, PTPRK, ARHGAP4, DUSP10, EMILIN1, TIMP1, MYOCD, ARAP3, DCN, TMEFF2, ENG, CX3CR1, LRP1, CCL2, TIE1, PODN]
GO:0030335;positive regulation of cell migration;7.0;0.5846489169746516;0.6432438237445264;8.22453031427283;157.26390226612122;3.6656062881777913;0.005263481280523835;0.5383786413027378;[MYLK, LGALS3, C3AR1, AKT1, IL1R1, ACTN4, PFN1, FPR2, PLA2G7, EPB41L5, PDGFD, PDGFC, NCKAP1L, S100A14, PLCG1, ELANE, LYN, CCR1, JUN, TNFSF14, PLK2, PPBP, PTK2, NOX4, NRP1, NRP2, RAC2, CTSH, CCR7, CCR6, CCR2, ANXA1, ANXA3, GAB1, CEACAM6, IL1B, KIT, HBEGF, PTAFR, PTGS2, GNAI2, PAK1, GPNMB, CXCR2, PDPN, NTF3, FLNA, CCL19, CCL20, PF4, SEMA5B, CXCL13, TNF, SLC8A1, CXCL16, PYCARD, IL6R, PDGFRB, F2R, ADAM9, CD274, CD151, C5AR1, CORO1A, TGFB1, CXCL10, CXCL11, CXCL12, PTPRC, DOCK5, CXCL6, CXCL9, TNFAIP6, LAMC2, CXCL1, CXCL3, CXCL2, CXCL5, MMP9, FGR, IFNG, XCL1, P2RY6, CCL8, CCL7, CCL5, CCL4, CCL1, EGF, SEMA4B, LAMB1, MAPK14, TEK]
GO:0060740;prostate gland epithelium morphogenesis;5.0;0.811012628672052;0.6957473261969462;9.089527751759436;36.210638831009675;6.7325511899570465;0.001211937494214703;0.6345439928109722;[TNC]
GO:1905522;negative regulation of macrophage migration;9.0;0.8933024483968273;0.8428918493787028;9.533214072687796;296.2025090399906;7.8311634786251565;0.009913631412617212;0.7967266896635242;[STAP1, EMILIN1, MIF]
GO:1901164;negative regulation of trophoblast cell migration;8.0;1.0;0.875;9.628524252492122;362.8566342195128;8.16763571524637;0.012144484997557702;0.7926932703116032;[ARHGDIB, TIMP1]
GO:0043200;response to amino acid;5.0;0.6441938053840475;0.612337914552944;8.412128928167629;56.712201515420396;5.104244793218563;0.0018981063470534028;0.5512723279577749;[TNF, CTGF, ALAD, CHUK, ARG1, COL4A1, NAIP, PCNA, ABCB4, PDGFD, PDGFC, FYN, LYN]
GO:1903984;positive regulation of TRAIL-activated apoptotic signaling pathway;11.0;1.0;0.9324289523296623;9.628524252492122;491.41789768672834;8.67846133901236;0.016447314788180012;0.8762458687964789;[TIMP3, ATF3]
GO:1901203;positive regulation of extracellular matrix assembly;7.0;1.0;0.8509193652572005;9.628524252492122;123.61133381433942;8.16763571524637;0.004137160099788013;0.7686126355688037;[TGFB1, EMILIN1]
GO:0043687;post-translational protein modification;7.0;0.6467165523344657;0.6742776414244334;8.507933057105237;151.15475272427284;3.8799197600437285;0.005059013543235805;0.5493386422205575;[SKP2, ESCO2, SPARCL1, SDC2, SERPINA1, TIMP1, F5, PSMA5, PSMA6, PSMA3, PSMA4, PSMA2, PSMC6, PSMC2, NUCB1, TNC, MEN1, FBXW2, PSMD14, IGFBP7, NAE1, WFS1, COPS5, CCDC22, UBE2M, LAMB1]
GO:0006469;negative regulation of protein kinase activity;10.0;0.6835726970475526;0.7570273603846966;9.223059144383958;1097.0598301796;4.243684138952949;0.03671760522636433;0.6322632160784685;[PYCARD, PPP2R1A, AKT1, MEN1, PAQR3, TSC2, SFRP2, PRKAR1B, FLRT2, PRKAR2B, SFN, LYN, CAV1, PTPRC, PKIG, CDKN1A, LRRC4, TNFAIP3, PTPN22, HHEX, DUSP10, LRRTM4, NUP62, DUSP2, MYOCD, DUSP1, IRAK3, DUSP6, DCN, CEACAM1, IL1B, LRRC19, CDKN2C, PODN, PTPN6, PKN1]
GO:1904956;regulation of midbrain dopaminergic neuron differentiation;9.0;0.8259837884571596;0.8092325194088689;9.485423408851448;65.91985791570636;8.16763571524637;0.002206278320418209;0.8139338954918922;[SFRP2]
GO:0010718;positive regulation of epithelial to mesenchymal transition;6.0;0.811012628672052;0.7286266269261705;9.377209824211215;170.70262580884207;5.9928839937622085;0.005713263263432726;0.6295966787287501;[TGFB1I1, EPB41L5, PDPN, TGFB1, IL1B, EZH2, ENG]
GO:0030206;chondroitin sulfate biosynthetic process;8.0;1.0;0.875;9.628524252492122;416.1007025877491;6.558197802812269;0.013926516049292044;0.7103865406232063;[DCN, CSPG4]
GO:0001960;negative regulation of cytokine-mediated signaling pathway;7.0;0.7140352122741334;0.7079369713942671;8.965230035081857;244.80256319284138;5.8067817141283475;0.008193321482061134;0.6478784521606894;[CCL5, STAP1, ARG1, NR1H2, IL1R2, CAV1, IRAK3, MMP12, PTPRC, PXDN, PADI2]
GO:0045471;response to ethanol;5.0;0.9326813400603323;0.7565816818910864;9.523163736834295;69.73224034292265;5.006389003214805;0.0023338753293357085;0.5462679783062231;[TNC, EEF1B2, ALAD, CLDN3, IL1B, CLDN7, S100A8, PSMD14, CCL7, CNR1, FYN, GSN]
GO:1900747;negative regulation of vascular endothelial growth factor signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;326.5542293843208;8.16763571524637;0.01092947617776706;0.7686126355688037;[DCN]
GO:0071230;cellular response to amino acid stimulus;6.0;0.7140352122741334;0.6801379187272112;8.962045319014338;283.89643900763554;5.6339389012889365;0.009501758323378283;0.6112402100070131;[ABCB4, TNF, PDGFD, PDGFC, FYN, COL4A1]
GO:0030208;dermatan sulfate biosynthetic process;8.0;1.0;0.875;9.628524252492122;665.197598747091;7.292166977892469;0.022263564991093197;0.747921758369865;[CSPG4, DCN]
GO:0030449;regulation of complement activation;8.0;0.6873818243518346;0.7186909121759173;9.298282565621545;245.7676390307622;5.076593261888053;0.008225621701844479;0.6346172154986847;[C1QA, C5AR1, IGHG1, IGKC, CD19, IGLV1-44, C3AR1, CR2, CR1, IGKV3-20]
GO:0030207;chondroitin sulfate catabolic process;8.0;1.0;0.875;9.628524252492122;411.79540990145875;7.138016298065211;0.01378242177759377;0.7400384854347593;[CSPG4, DCN]
GO:0010719;negative regulation of epithelial to mesenchymal transition;6.0;0.8259837884571596;0.7361122068187242;9.434368238051164;171.1659509920613;6.481236761676141;0.005728770340349481;0.6545710619905948;[SFRP2]
GO:0001569;branching involved in blood vessel morphogenesis;7.0;1.0;0.8509193652572005;9.628524252492122;53.5045405888233;6.375876246018314;0.0017907488225476112;0.6769819729871445;[NRP1, PLXND1, SFRP2, COL4A1, ENG]
GO:0010951;negative regulation of endopeptidase activity;10.0;0.7671156992804218;0.7987988615011312;9.446202695698167;500.3238742612354;4.2676852910524925;0.016745389809270216;0.6334906361130068;[SPINT2, RPS6KA1, AKT1, POR, SFRP2, SPINT1, SLPI, NAIP, SFN, TNFSF14, TNFRSF10C, CRIM1, TNFRSF10B, DHCR24, SERPINA1, TIMP3, TIMP1, CR1, SERPINB9, TNFRSF1B, MMP9, PAX2, COL6A3, LTF, SERPINB10, NLRC4, PTGS2, SPOCK3]
GO:0060070;canonical Wnt signaling pathway;8.0;0.6729672293956388;0.7114836146978194;8.391761625343195;31.415129658942366;5.233778845410465;0.0010514361179036673;0.6426556935498979;[LRRK2, CDH3, FZD5, EGF, TMEM64, NR4A2, HOXB9, SFRP2, SDC1, LGR4]
GO:0030167;proteoglycan catabolic process;7.0;0.9326813400603323;0.8172600352873667;9.585964638073326;476.31662907080806;8.390779266560578;0.01594188891786456;0.7800242071602487;[ADAMTS12]
GO:0071356;cellular response to tumor necrosis factor;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;4.973052582947213;0.0027327542132076126;0.5774424529526606;[PID1, PYCARD, TCL1A, AKT1, CHUK, CHI3L1, XCL1, CCL13, CALCA, ADAMTS12, CCL8, CCL7, CCL5, CCL4, CCL2, CCL1, CD58, CCL19, CCL18, CCL23, CCL20, MAPK14, NFKB1]
GO:0070542;response to fatty acid;5.0;0.6696747006330769;0.6250783621774587;8.578702127993445;43.78950961223322;5.382624473008031;0.0014655954787213788;0.5655086777281872;[PID1, TNC, CTGF, ALAD, AKT1, FFAR2, CCR7, CD36, PTGDR, DGAT2, ACSL1, TGFBR3, IL1B, TLR2, PTGER2, PTAFR, PTGS2, P2RY6, CCL19]
GO:0060071;Wnt signaling pathway, planar cell polarity pathway;9.0;0.7436939687323844;0.7680876095464813;9.094441766561864;99.0414819593438;5.825829909099042;0.0033148292696323837;0.694173837660411;[CELSR1, AP2M1, CTHRC1, FZD5, VANGL1, SFRP2, PFN1]
GO:0051901;positive regulation of mitochondrial depolarization;8.0;1.0;0.875;9.628524252492122;107.42585434118669;7.57984905034425;0.0035954466678074135;0.7626338329336335;[DCN]
GO:0010950;positive regulation of endopeptidase activity;10.0;0.7436939687323844;0.7870879962271125;9.418803721510052;499.32903666023907;4.7018998124466425;0.01671209349006058;0.6556963869301439;[TNF, CTGF, PYCARD, F2R, SFRP2, S100A8, PSMD14, NLRP3, LYN, TNFRSF10B, FASLG, CTSH, CR1, LCK, NLRC4, HSPD1, FYN, GSN, HSPE1, NLRP12, P2RX1]
GO:0060452;positive regulation of cardiac muscle contraction;9.0;0.811012628672052;0.801746939516315;9.466005322994347;171.4016794204555;7.379178354882098;0.005736659958706022;0.7736121494158466;[KCNQ1, CTGF]
GO:0014012;peripheral nervous system axon regeneration;8.0;1.0;0.875;9.628524252492122;97.89308359404764;8.16763571524637;0.00327639340983735;0.7926932703116032;[TNC]
GO:2001044;regulation of integrin-mediated signaling pathway;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;41.8512380110395;7.212124270218933;0.0014007232725606145;0.6919486831672181;[BST1, FLNA, TIMP1, CD177]
GO:0007162;negative regulation of cell adhesion;5.0;0.5651597194614189;0.5728208715916296;7.400047131651798;38.26822196421712;4.255612709818223;0.001280802949978559;0.5078732437472537;[, CD86, PLXND1, CD80, TNC, SPINT2, LGALS3, CDH1, ARHGDIA, ARHGDIB, TNR, HOXA7, MEN1, LAG3, ACTN4, CLDN7, CD274, TACSTD2, EPB41L5, PAG1, TGFB1, JAG1, PTK2, CXCL12, PTPRC, BCL6, IFNA2, PTPN22, ARHGAP6, CTLA4, HAVCR2, ANXA1, ARG1, PAWR, PDCD1LG2, CEACAM1, XCL1, GPNMB, EPCAM, JAM2, LILRB1, LILRB2, CD9, PTPN6, FCGR2B, SIPA1]
GO:1904684;negative regulation of metalloendopeptidase activity;11.0;0.9326813400603323;0.8987696223598284;9.59953671561887;1127.0177719714866;8.390779266560578;0.03772027057774158;0.8615337942327104;[TIMP3]
GO:0090244;Wnt signaling pathway involved in somitogenesis;8.0;1.0;0.875;9.628524252492122;31.415129658942366;8.390779266560578;0.0010514361179036673;0.8041048419030481;[SFRP2]
GO:0045599;negative regulation of fat cell differentiation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;114.62387697121986;5.948432231191374;0.0038363580074348307;0.6273234135236593;[TGFB1I1, TNF, FOXO1, TGFB1, JAG1, SORT1]
GO:0006355;regulation of transcription, DNA-templated;9.0;0.4043225613388953;0.5984019058497367;6.838723401371219;245.35026186902695;1.5478292109445575;0.008211652463856259;0.4753966830094131;[NUP107, SLA2, SPIB, AKT1, ATF3, JUN, JAG1, JUP, PKIG, CHAF1B, FOS, MMP12, MED23, PTAFR, ZNF467, ATAD2, PKN1, LGR4, GMNN, EFEMP1, BLM, CIITA, HHEX, E2F5, E2F7, POU2AF1, SMARCAL1, TNFSF11, FBXO5, BTK, TGFA, PKHD1, EGR1, EGR2, EGR3, POLA1, SYK, IL1B, KIT, PCNA, NR3C2, CARD11, CAV1, TCF4, MXD1, TNFAIP3, MYOCD, NUP133, IRAK3, ELF3, FBP1, CD4, PHB2, PRKCQ, NUP85, PRDM16, NFE2, CDKN1A, ZNF367, EPCAM, NR1H2, ELP4, PF4, PLXND1, TNF, TLE4, MAP2K2, MAP2K6, COPS5, BCL6, CCDC22, SLC26A3, LBH, EMILIN1, RFC1, XCL1, CEBPE, NLRC4, POLR2K, POLR2L, DNAJA3, PPIL4, PPP2R1A, RPS6KA1, FLT3LG, SIK1, AHCTF1, IFNA2, PRL, XPO1, VAV1, MLF2, HCK, TLR6, TLR4, TLR2, GRHL2, CD40LG, HOXA11, HOXA10, NLRP3, CBX4, KDM5D, SLC40A1, DCN, DNM2, PFDN5, LTF, RBMX, PID1, EHMT2, MEF2A, MEF2C, PADI2, PADI4, HACE1, EZH2, PSMA6, BTAF1, STAT4, FLNA, USP9Y, PSMC6, PSMC2, CCNT2, RUVBL2, RUVBL1, S100A8, MAZ, TNFRSF11A, FOXO1, NFKB1, CXCL10, MYD88, FASLG, PPP1R12A, BDP1, LRP2, CCNH, UXT, TMPO, SFRP2, PCBP3, ZNF700, OR7D2, CD28, PTPRK, BRCA2, CD3D, CD36, RGMA, NLRP12, IL17A, CD86, CD80, CCNE1, CALCA, HMGA1, INHBA, HMGB2, ARHGEF10L, AFF3, NUP62, PSRC1, CREB5, TAF9, EGF, MAPK14, NUP35, RAN, EHF, HOXA9, MYB, HOXA3, HOXA7, HOXA5, HOXA4, HOXB9, HOXB4, HOXB3, HOXB2, HOXB7, HOXB6, HOXB5, ELANE, NKX2-3, FZD5, CDC6, TGFB1I1, HAVCR2, BRD2, ANXA3, NFAM1, PAWR, PAX5, PAX2, AES, ENG, GTF2H1, PYCARD, DACH1, CDH1, MEN1, F2R, NACC2, WFS1, HOPX, CNOT3, MAFF, CHUK, TRAF1, SMARCD3, RBBP8, ZNF503, KLF1, KLF8, KLF5, MNDA, ZNF608, EDNRB, CHEK1, DPF3, SLC11A1, EBF1, RUNX2, PFN1, BEX1, SP140, NHLH2, BCL11B, BCL11A, RHOG, RHOH, SGK1, LILRB1, CAMK4, ARID4A, ARID4B, CHCHD3, BASP1, ADRB2, TGFB1, NR4A2, NFKBIA, NR4A1, LIN28A, JMY, CREBZF, TMEM100, CKAP2, TGFBR3, IFNG, DLL1, HSPD1, MEIS2, MEIS1]
GO:0045597;positive regulation of cell differentiation;5.0;0.4493394816318884;0.5149107526768645;6.573475401781711;82.53300662006848;2.970244267288293;0.0027623054566900678;0.44213944182052767;[CYFIP1, MYB, AKT1, HOXA5, MEF2A, MEF2C, SPINT1, AGTR1, HOXB4, EPB41L5, PRDM16, SFN, NCKAP1L, LYN, JUN, JAG1, EZH2, TGFB1I1, ANXA1, FOS, PAX2, ENG, PTGS2, FLNA, CCL19, IL12RB1, TMEM64, PF4, PLXND1, FMR1, TNF, CTGF, CDH5, OLFM4, TACSTD2, NFKB1, CXCL12, BCL6, DUSP10, ADAMTS20, CX3CR1, NLGN1, SMARCD3, LRP2, RAB21, FYN, CTHRC1, KLF5, CPNE5, RPS6KA1, TNFSF11, FLT3LG, RUNX2, BTC, POR, SFRP2, BTK, EPHA3, INPP5D, CCR1, MSR1, EGR3, TNFSF14, VNN1, CD24, ROBO2, NRP1, CD36, CCR2, SYK, CEACAM1, IL1B, KIT, TLR2, CXCR4, PAK1, PDPN, LILRB2, IL17A, SCARB2, CD86, CD83, CD80, HOXA11, ARHGDIA, IL6R, LTBP3, NLRP3, TGFB1, SYT2, INHBA, LIN28A, TCF4, DOCK5, CXCL9, HMGB2, TMEM100, MYOCD, DNM2, ZAP70, IFNG, LTF, CNR1, MAPK14, CD4, ACIN1]
GO:0061304;retinal blood vessel morphogenesis;5.0;1.0;0.7902410118609202;9.628524252492122;25.965694757875163;8.16763571524637;8.690484359379531E-4;0.7079342821725234;[COL4A1]
GO:1902548;negative regulation of cellular response to vascular endothelial growth factor stimulus;6.0;0.8933024483968273;0.7697715367885581;9.461470167828956;111.25895428834873;7.9853141584524145;0.003723737073472939;0.7314896500084853;[ADAMTS12, DCN]
GO:0090090;negative regulation of canonical Wnt signaling pathway;8.0;0.7866048967936545;0.7683024483968273;9.283683766200392;236.99226377157444;4.932886541221878;0.00793191778924446;0.6272680471207706;[RUVBL2, TLE4, AES, SFRP2, PFDN5, FOXO1, CTHRC1, EGR1, CAV1, TMEM64, MAPK14]
GO:0060739;mesenchymal-epithelial cell signaling involved in prostate gland development;5.0;0.9326813400603323;0.7565816818910864;9.4949928598676;28.889074499638813;9.777073627680469;9.668913250238256E-4;0.7902410118609202;[TNC]
GO:0045087;innate immune response;4.0;0.6799073451904818;0.5899536725952409;8.162187183698695;26.470038109745843;3.422703586883119;8.859283540455166E-4;0.42503722060519694;[, SLA2, LGALS3, TRBC1, RNASE6, RNASE3, MIF, SLPI, BTK, PADI4, TRIM10, NAIP, LY9, KLRK1, SLAMF7, IGHA1, LYN, KIR2DS1, KIR2DS2, SH2D1A, KIR2DS4, KIR2DS5, PTK2, MARCO, VNN1, IFNA5, IFNA4, IGHM, ITK, IFNA7, IFNA2, IFNA8, CAMP, HAVCR2, ANXA1, FCER1G, SYK, ARG1, TLR1, HCK, IGHD, TLR8, TLR10, TLR7, TLR6, TLR5, TLR4, TLR2, C1QA, LILRA5, IGKC, CARD9, KIR3DL1, LGR4, PYCARD, IGHG1, GRAP2, CLEC5A, CD177, IFNA14, IFNA16, CD180, CLEC4D, S100A8, IFNA10, BLK, LY96, CORO1A, CLEC7A, NLRP3, IFNA21, TGFB1, DEFA4, DEFA1, BMX, NFKB1, LCN2, KLRD1, ITGAM, KIR3DS1, CRISP3, HMGB2, TREM2, TREM1, SIRPB1, CR2, CR1, CHUK, FGR, ZAP70, LCK, LTF, COLEC12, UNC93B1, HIST1H2BK, NLRC4, FYN, CSK, CD6, PTX3, PTPN6, CD244]
GO:0046330;positive regulation of JNK cascade;12.0;0.8436909121759173;0.8699657686781033;9.567899630675686;1762.0380321839782;4.909539177224887;0.058973827205923174;0.6991943744303455;[TNF, CTGF, PYCARD, TNFSF11, CCR7, MAP4K1, SYK, IL1B, TLR6, TNFRSF11A, PAK1, CCL19, FZD5, CARD9, CD40LG, PKN1, LTBR, FCGR2B]
GO:0043066;negative regulation of apoptotic process;7.0;0.5640623033008358;0.6329505169076184;7.792313020693233;81.07407142393629;2.9735683700721314;0.0027134762086319553;0.5029877899877601;[PHB2, AKT1, PROK2, MEF2C, CLDN7, PRKCQ, SLC30A10, FIGNL1, SFN, NCKAP1L, BARD1, JUN, PLK2, AZU1, CDKN1A, CHL1, TIMP1, ANXA1, DUSP1, ANXA5, SERPINB9, PAX2, PTGS2, UNG, NTF3, FLNA, CCL19, GABRA5, PF4, TNF, CLEC5A, F2R, MSH2, BLM, CORO1A, FOXO1, WFS1, TNFRSF10C, TNFRSF10B, DHCR24, NFKB1, CXCL12, COPS5, BCL6, MYD88, LRRK2, FASLG, TNFRSF1B, ADAMTS20, CX3CR1, LRP1, NLRC4, CCL5, CCL2, FYN, TIE1, IL2RB, SLC46A2, LGALS3, TCL1A, EDNRB, RPS6KA1, EPHB1, FLT3LG, MIF, BTC, POR, SFRP2, EPHA3, NAIP, PKHD1, EGR3, BCL11B, TNFSF14, PTK2, VNN1, CD28, NRP1, CTSH, CCR7, CCR5, FCER1G, HCK, CEACAM6, IL1B, KIT, GNAI2, CXCR2, PDPN, LILRB1, CD40LG, GRINA, COMP, ARHGDIA, PDGFRB, GHSR, C5AR1, PSEN2, CBX4, CAV1, NR4A2, NFKBIA, HMGB2, SLC40A1, TNFAIP3, NUP62, MYOCD, MMP9, NDUFS3, LTF, BCL2A1, TAF9, DLL1, HSPD1, TEK]
GO:0070373;negative regulation of ERK1 and ERK2 cascade;11.0;1.0;0.9324289523296623;9.628524252492122;1180.902522994834;5.6339389012889365;0.039523744701365535;0.7205488497465309;[PTPRR, DUSP10, TIMP3, CSK, EMILIN1, LYN, DUSP1, DUSP6, NLRP12, TLR4, ATF3]
GO:0006508;proteolysis;5.0;0.5517781253862416;0.5661300745540411;7.338517941704937;47.85814540089318;2.5985281439167696;0.001601769057033345;0.42312986198474045;[, UQCRC1, PRKCQ, UQCRC2, ENPEP, ADAMTS12, ELANE, BARD1, ST14, ACE, HACE1, AZU1, TGFB1I1, OLR1, MMP12, PSMA5, PSMA6, PSMA3, PSMA4, PSMA2, FAM105A, ADAM28, USP9Y, F11, PSMC6, PSMC2, APEH, IGHG1, RUVBL1, FBXW2, ADAM2, ADAM9, ADAM7, IGLV1-44, CLCA4, WFS1, DHCR24, NFKB1, COPS5, ADAMTS1, ADAMTS20, HM13, RNF24, EIF3F, ANPEP, SKP2, CTSS, CTSH, CTSG, MME, C1QA, IGKC, RANBP2, RANBP1, ADAM12, PRTN3, PSMD14, PSEN2, ADRB2, TRHDE, DPP4, NLRP3, TGFB1, NFKBIA, IGKV3-20, TNFAIP3, MMP8, MMP9, LTF, RBMX]
GO:0070374;positive regulation of ERK1 and ERK2 cascade;11.0;0.9326813400603323;0.8987696223598284;9.604993755081928;1178.864923326294;4.330336256014159;0.03945554807418015;0.6538825498434562;[PHB2, TNF, CTGF, PYCARD, TNFSF11, EPHB1, PDGFRB, F2R, MIF, EPHA3, C5AR1, FPR2, TNFRSF11A, SLC30A10, PDGFD, PDGFC, CCR1, JUN, TGFB1, MARCO, NOX4, NRP1, TREM2, PTPN22, CCR7, CD36, HAVCR2, IL1B, KIT, CHI3L1, XCL1, CCL13, GNAI2, CCL8, GPNMB, CCL7, CCL5, CCL4, CCL2, CCL1, CCL19, CCL18, CCL23, CCL20, TIE1, CD4, TEK]
GO:0043065;positive regulation of apoptotic process;7.0;0.5587538620495764;0.6302962962819887;7.806911820114386;80.91235068524658;3.3969510907807043;0.0027080635610472266;0.5246396020141064;[MYB, AKT1, HOXA5, MEF2C, ATF3, SFN, PLCG1, BARD1, LYN, JUN, NOX4, CTLA4, TIMP3, ANXA1, DUSP1, PAWR, DUSP6, AES, PTGS2, FGD3, FGD4, GSN, BIK, G0S2, TNF, CTGF, PYCARD, F2R, MELK, MAL, S100A8, CD274, FOXO1, NACC2, MAP2K6, TNFRSF10B, BCL6, PLEKHF1, FASLG, LCK, NLRC4, CCL5, CCL2, P2RX1, MNDA, PPP2R1A, SFRP2, SIK1, INPP5D, TP53BP2, TNFSF12, ITM2C, CTSH, VAV1, IL1B, CXCR2, SORT1, LILRB1, PPP1CA, NLRP12, CD40LG, PDGFRB, NLRP3, TGFB1, CAV1, INHBA, EIF2S1, JMY, UBE2M, MMP9, DNM2, IFNG, BCL2A1, HSPD1, CNR1, HSPE1, LTBR]
GO:0071347;cellular response to interleukin-1;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;5.446340287394138;0.0027327542132076126;0.6016464081682054;[CCL13, ADAMTS12, PYCARD, CCL8, CCL7, CCL5, CCL4, CCL2, CCL1, CCL19, CCL18, CCL23, CCL20, KMO, NFKB1, CHI3L1, XCL1, RBMX, IL17A]
GO:0032331;negative regulation of chondrocyte differentiation;7.0;0.8933024483968273;0.7975705894556142;9.567899630675686;230.26794502196225;6.781341354126479;0.007706860892188918;0.6977174774718518;[EFEMP1, ADAMTS12]
